Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-pLipo
- Development stage
- Preclinical
- Lead developer
- Central Japan International Medical Center
- Modality
- Antibody-Based Therapeutics, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**PSMA-pLipo** is a preclinical, prostate cancer-targeted liposomal gene-therapy candidate. It consists of liposomes carrying a prostate-specific antigen promoter-driven perforin expression vector and decorated with an anti-prostate-specific membrane antigen antibody for preferential delivery to PSMA-positive prostate cancer cells. Following delivery, PSA promoter activity is intended to drive perforin expression selectively in PSA-expressing tumor cells; perforin-mediated cytotoxicity is enhanced in the presence of cytotoxic immune cells. In reported in-vitro and 22Rv1DR xenograft studies, intravenous PSMA-pLipo inhibited growth of docetaxel-resistant, PSA-positive and PSMA-positive prostate cancer cells. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/82/12_Supplement/5332/699577/Abstract-5332-Prostate-cancer-targeting-therapy))
- Other names
- PSMA-pLipo
02
Targets
PRF1 (Zinc finger protein 395)PSMA (Prostate-specific membrane antigen)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on PSMA-pLipo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-pLipo.